Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Revenue: 2009-2025

Historic Revenue for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to $13.9 million.

  • Aytu Biopharma's Revenue fell 16.21% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.7 million, marking a year-over-year decrease of 0.38%. This contributed to the annual value of $66.4 million for FY2025, which is 1.84% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Revenue is $13.9 million, which was down 8.24% from $15.1 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Revenue peaked at $30.7 million during Q2 2023, and registered a low of $13.5 million during Q1 2021.
  • In the last 3 years, Aytu Biopharma's Revenue had a median value of $16.6 million in 2024 and averaged $18.1 million.
  • Per our database at Business Quant, Aytu Biopharma's Revenue skyrocketed by 79.48% in 2022 and then plummeted by 52.52% in 2024.
  • Aytu Biopharma's Revenue (Quarterly) stood at $23.1 million in 2021, then increased by 13.64% to $26.3 million in 2022, then decreased by 28.66% to $18.7 million in 2023, then fell by 13.48% to $16.2 million in 2024, then fell by 16.21% to $13.9 million in 2025.
  • Its Revenue stands at $13.9 million for Q3 2025, versus $15.1 million for Q2 2025 and $18.5 million for Q1 2025.